Autoimmune complications and clinical outcomes of herpes simplex encephalitis in children: A case series

Abstract

Objective: To report the neurologic prognosis and autoimmune complications of 16 cases of childhood herpes simplex virus encephalitis. Methods: The study was conducted at Şanlıurfa Training and Research Hospital, Turkey from June 2017 to August 2019. The study included 16 pediatric patients aged between 6 months and 17 years (median age 77.7 months) who were diagnosed with herpes simplex virus type 1 encephalitis by pediatric infectious disease and pediatric neurology clinics. Patients were followed using patient records, and interviews at the pediatric neurology clinic or via the telephone. Clinical and demographic data, received therapies, neurologic prognosis and complications were evaluated. Results: Patients with and without autoimmune encephalitis were compared in terms of age, sex, symptom duration before treatment, initial cerebrospinal fluid protein, glucose, red blood count and white blood count but no significant difference was found. Autoimmune complications were seen in four patients. N-methyl-D-aspartate encephalitis was observed in three patients and choreoathetosis was seen in one patient. The average follow-up period was 48.3 months. Twenty-five percent of the patients were receiving multiple antiepileptic drug (AED) treatment, 43.8% were receiving single AED treatment and 31.3% were not receiving AED treatment at the end of the follow-up. Motor disability was observed in 12.5% and drug-resistant epilepsy was observed in 6.3% who had autoimmune complications. Conclusions: Seizures and movement disorders were controlled with immunotherapy and autoantibodies should be studied routinely. Treatment should be started early upon recognition of autoimmune complications through follow-up by measuring autoantibody levels and clinical examination results. Effective prevention and curative treatment modalities are needed to avoid herpes simplex virus encephalitis complications.

Keywords

Herpes simplex virus encephalitis / Autoimmune complications / Epilepsy / Children / Steroid / Prognosis

References

[1] Fraley CE, Pettersson DR, Nolt D. Encephalitis in previously healthy children. Pediatr Rev 2021; 42(2):68-77.

[2] Miller S, Mateen FJ, Aksamit Jr. AJ. Herpes simplex virus 2 meningitis: A retrospective cohort study. J Neurovirol 2013; 19(2):166-171.

[3] Erickson TA, Muscal E, Munoz FM, Lotze T, Hasbun R, Brown E, et al. Infectious and autoimmune causes of encephalitis in children. Pediatrics 2020; 145(6):e20192543.

[4] Steiner I. Herpes simplex virus encephalitis: New infection or reactivation? Curr Opin Neurol 2011; 24(3):268-274.

[5] Solomon T, Michael BD, Smith PE, Sanderson F, Davies NWS, Hart IJ, et al. Management of suspected viral encephalitis in adults. Association of British Neurologists and British Infection Association National Guidelines. J Infect 2012; 64(4):347-373.

[6] Michaeli O, Kassis I, Shachor-Meyouhas Y, Shahar E, Ravid S. Long-term motor and cognitive outcome of acute encephalitis. Pediatrics 2014; 133:546-552.

[7] Prüss H. Postviral autoimmune encephalitis. Curr Opin Neurol 2017; 30:327-333.

[8] Looker JK, Magaret AS, May MT, Turner KME, Vickerman P, Gottlieb SL, et al. Global and regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012. PLoS One 2015; 10(10):e0140765.

[9] Uyar O, Laflamme N, Piret J, Venable MC, Carbonneau J, Zarrouk K, et al. An early microglial response is needed to efficiently control herpes simplex virus encephalitis. J Virol 2020; 94(23):e01428-20.

[10] Reinert LS, Rashidi AS, Tran DN, Katzilieris-Petras G, Hvidt AK, Gohr M, et al. Brain immune cells undergo cGAS/STING-dependent apoptosis during herpes simplex virus type 1 infection to limit type I IFN production. J Clin Invest 2021; 131(1):e136824.

[11] Kavaklıoğlu BC, Çoban E, Şen A, Söylemezoğlu E, Aldan MA, Ataklı D, et al. Review of viral encephalitis cases seen at a tertiary care center in Turkey: Focus on herpes simplex type 1. Noro Psikiyatr Ars 2017; 54(3):209-215.

[12] Perez de Diego R, Mulvey C, Casanova JL, Godovac-Zimmermann J. Proteomics in immunity and herpes simplex encephalitis. Expert Rev Proteomics 2014; 11(1):21-29.

[13] Li Q, Fu N, Han Y, Qin J. Pediatric autoimmune encephalitis and its relationship with infection. Pediatr Neurol 2021; 120:27-32.

[14] Rozenberg F. Acute viral encephalitis. Handb Clin Neurol 2013; 112:1171-1181.

[15] Armangue T, Spatola M, Vlagea A, Mattozzi S, Cárceles-Cordon M, Martinez-Heras E, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: A prospective observational study and retrospective analysis. Lancet Neurol 2018; 17:760-772.

[16] Sili U, Kaya A, Mert A. Herpes simplex virus encephalitis: Clinical manifestations, diagnosis and outcome in 106 adult patients. J Clin Virol 2014; 60:112-118.

[17] Lee EJ, Jang HN, Cho HS, Bae E, Lee TW, Chang S, et al. The incidence, risk factors, and clinical outcomes of acute kidney injury (staged using the RIFLE classification) associated with intravenous acyclovir administration. Ren Fail 2018; 40:687-692.

[18] Kullnat MW, Morse RP. Choreoathetosis after herpes simplex encephalitis with Basal Ganglia involvement on MRI. Pediatrics 2008; 121:1003-1007.

[19] Stahl JP, Mailles A. Herpes simplex virus encephalitis update. Curr Opin Infect Dis 2019; 32:239-243.

[20] Marcus L, Ness JM. Pediatric N-Methyl-d-Aspartate (NMDA) receptor encephalitis, with and without herpes encephalitis. J Child Neurol 2021; 36(9):743-751.

[21] Quade A, Rostasy K, Wickström R, Aydin ÖF, Sartori S, Nosadini M, et al. Autoimmune encephalitis with autoantibodies to NMDAR1 following herpes encephalitis in children and adolescents. Neuropediatrics 2023; 54(1):14-19.

[22] Kamei S, Sekizawa T, Shiot Ha H, Mizutani T, Itoyama Y, Takasu T, et al. Evaluation of combination therapy using aciclovir and corticosteroid in adult patients with herpes simplex virus encephalitis. J Neurol Neurosurg Psychiatry 2005; 76(11):1544-1549.

[23] Meyding-Lamade U, Oberlinner C, Rau P, Seyfer S, Heiland S, Sellner J, et al. Experimental herpes simplex virus encephalitis: A combination therapy of acyclovir and glucocorticoids reduces long-term magnetic resonance imaging abnormalities. J Neuro Virol 2003; 9:118-125.

[24] Genç HM, Yalçın EU, Sayan M, Asuman Bayhan A, Öncel S, Arısoy ES, et al. Clinical outcomes in children with herpes simplex encephalitis receiving steroid therapy. J Clin Virol 2016; 80:87-92.

[25] Carrascosa-Garcıa P, Oviedo-Melgares L, Torres-Fernandez D, Blazquez-Gamero D, Armangue T, Vila-Bedmar S, et al. Rituximab as second-line treatment in anti-NMDAR encephalitis after herpes simplex encephalitis in children. Indian J Pediatr 2022; 89(10):1031-1033.

[26] Nosadini M, Thomas T, Eyre M, Anlar B, Thais Armangue T, Benseler SM. International consensus recommendations for the treatment of pediatric NMDAR antibody encephalitis. Neurol Neuroimmunol Neuroinflamm 2021; 8:e1052.